Short answer
Penumbra Inc (PEN) filed its Q2 2017 10-Q quarterly report on Aug 8, 2017 for the quarter ended Jun 30, 2017.
Penumbra Inc Q2 2017 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q2 revenue $80.6M, up 23.8% YoY from $65.1M
- Q2 gross margin 63.2% vs 63.7% YoY; operating margin (1.6%) vs (1.0%)
- Best segment: Neuro revenue $56.2M, up 23.9%; Peripheral Vascular $24.4M, up 23.5%
- Cash $76.6M vs $13.2M, operating cash flow $2.8M vs $(8.2)M in six months
- Outlook: continued R&D, salesforce and international investment; competition, product launches and quarterly variability headwinds
Risk Factors
- No material changes or new risk factors since the December 31, 2016 Form 10-K
- Carried-forward risks include regulatory compliance, product liability, competition, operations, liquidity, and financial exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Penumbra Inc quarterly reports
- Q3 2019 10-QFiled Nov 7, 2019
- Q2 2019 10-QFiled Aug 6, 2019
- Q1 2019 10-QFiled May 7, 2019
- Q3 2018 10-QFiled Nov 5, 2018
- Q2 2018 10-QFiled Aug 7, 2018
- Q1 2018 10-QFiled May 8, 2018
- Q3 2017 10-QFiled Nov 7, 2017
- Q1 2017 10-QFiled May 9, 2017
- Q3 2016 10-QFiled Nov 3, 2016
- Q2 2016 10-QFiled Aug 9, 2016
- Q1 2016 10-QFiled May 9, 2016
- Q3 2015 10-QFiled Nov 12, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.